G. Ranges

发表

Effect of cytotoxic monoclonal antibody depletion of T-lymphocyte subpopulations on bleomycin-induced lung damage in C57BL/6J mice.

M. Hacker, D. Janick-Buckner, G. Ranges, 1989, Toxicology and applied pharmacology.

Inhibition of cytotoxic T cell development by transforming growth factor beta and reversal by recombinant tumor necrosis factor alpha

T. Espevik, I. Figari, M. Palladino, 1987, The Journal of experimental medicine.

Tumor necrosis factor receptor p75 mediates cell-specific activation of nuclear factor kappa B and induction of human cytomegalovirus enhancer.

T. Espevik, A. Sundan, U. Nonstad, 1994, The Journal of biological chemistry.

Tumor necrosis factor alpha/cachectin is a growth factor for thymocytes. Synergistic interactions with other cytokines

A. Cerami, C. Dinarello, A. Zlotnik, 1988, The Journal of experimental medicine.

The release of soluble p55 TNF receptor from U937 cells studied by a new p55 immunoassay.

N. Liabakk, T. Espevik, A. Sundan, 1993, Journal of immunological methods.

Chromosome assignments of the human TNF p55 and p75 receptor genes.

F. Ruddle, M. Kamarck, G. Ranges, 1992, The Journal of experimental zoology.

Distinct Roles of the Two Tumor Necrosis Factor (TNF) Receptors in Modulating TNF and Lymphotoxin Effects (*)

T. Espevik, A. Sundan, A. Medvedev, 1996, The Journal of Biological Chemistry.

Anti‐tumor necrosis factor receptor and tumor necrosis factor agonist activity by an anti‐idiotypic antibody

T. Espevik, G. Ranges, G. Mitra, 1992, European journal of immunology.

Tumor necrosis factor-alpha as a proliferative signal for an IL-2-dependent T cell line: strict species specificity of action.

M. Palladino, R. Aiyer, G. Ranges, 1989, Journal of immunology.

Genomic cloning and heterologous expression of human differentiation-stimulating factor.

D. Goeddel, Y. Yamamoto‐Yamaguchi, G. Ranges, 1989, DNA.

Prevention of type II collagen-induced arthritis by in vivo treatment with anti-L3T4

S. Sriram, G. Ranges, S. Cooper, 1985, The Journal of experimental medicine.

Alteration of bronchoalveolar lavage cell populations following bleomycin treatment in mice.

M. Hacker, D. Janick-Buckner, G. Ranges, 1989, Toxicology and applied pharmacology.

1-Phenyl-5-pyrazolyl ureas: potent and selective p38 kinase inhibitors.

J. S. Johnson, T. Turner, S. Wilhelm, 2000, Bioorganic & medicinal chemistry letters.

Successful treatment of experimental allergic encephalomyelitis with transforming growth factor-beta 1.

K. Flanders, S. Sriram, S. Sriram, 1991, Journal of immunology.

Suppression of murine collagen-induced arthritis with monoclonal anti-Ia antibodies and augmentation with IFN-gamma.

S. Sriram, G. Ranges, S. Cooper, 1988, Journal of immunology.

A synthetic mycobacterial heat shock peptide prevents adjuvant arthritis but not proteoglycan-induced synovitis in the rat

G. Ranges, C. Maniglia, H. Golden, 1991, Agents and Actions.

Functional relationships of Lyt-2 and Lyt-3 expression and T-cell cytotoxicity: a new model system.

L. Old, M. Palladino, H. Oettgen, 1985, Advances in experimental medicine and biology.

The involvement of human tumor necrosis factors-alpha and -beta in the mixed lymphocyte reaction.

G. Rice, T. Espevik, I. Figari, 1988, Journal of immunology.

Transforming growth factor-beta 1 (TGF-beta 1) and recombinant human tumor necrosis factor-alpha reciprocally regulate the generation of lymphokine-activated killer cell activity. Comparison between natural porcine platelet-derived TGF-beta 1 and TGF-beta 2, and recombinant human TGF-beta 1.

T. Espevik, I. Figari, M. Palladino, 1988, Journal of immunology.

Increased susceptibility to inoculated Lewis lung carcinoma (3LL) but unaltered tumor growth in mice treated with monoclonal antibody to L3T4 on mouse T-helper cells.

R. Klopp, W. Ershler, G. Ranges, 1989, Cancer investigation.

In vivo immunomodulation by monoclonal anti-L3T4. 1. Effects on humoral and cell-mediated immune response.

S. Sriram, G. Ranges, S. Cooper, 1987, Cellular immunology.

Suppression of T cell cytotoxicity by nude mouse spleen cells: reversal by monosaccharides and interleukin 2.

M. Palladino, H. Oettgen, G. Ranges, 1983, Journal of immunology.

Serotonin-activated signal transduction via serotonin receptors on Jurkat cells.

T. Aune, G. Ranges, M. Bombara, 1990, Journal of immunology.

p38 kinase inhibitors for the treatment of arthritis and osteoporosis: thienyl, furyl, and pyrrolyl ureas.

J. S. Johnson, S. Wilhelm, W. Scott, 2001, Bioorganic & Medicinal Chemistry Letters.

1-Phenyl-5-pyrazolyl ureas: potent and selective p38 kinase inhibitors.

J. S. Johnson, T. Turner, S. Wilhelm, 2000, Bioorganic & medicinal chemistry letters.

Development of T-cell function in relation to T-cell set diversification in nu/nu mice.

M. Palladino, G. Ranges, M. Scheid, 1986, Cellular immunology.

T cell development in normal and thymopentin-treated nude mice

E. Boyse, G. Goldstein, G. Ranges, 1982, The Journal of experimental medicine.

Flavonoids inhibit cytokine-induced endothelial cell adhesion protein gene expression.

M. Gerritsen, W. Carley, C. Perry, 1995, The American journal of pathology.

Interleukin-2 and aging: Decreased interleukin-2 production in healthy older people does not correlate with reduced helper cell numbers or antibody response to influenza vaccine and is not corrected in vitro by Thymosin α1

W. Ershler, G. Ranges, K. Roessner, 1985 .

Chronic therapy with recombinant tumor necrosis factor-alpha in autoimmune NZB/NZW F1 mice.

D. Wofsy, J. Greenspan, G. Ranges, 1989, Clinical immunology and immunopathology.

Therapeutic Mechanism and Efficacy of the Antibody–Drug Conjugate BAY 79-4620 Targeting Human Carbonic Anhydrase 9

Lila Adnane, A. Voznesensky, P. Trail, 2011, Molecular Cancer Therapeutics.

Cell contact between T cells and synovial fibroblasts causes induction of adhesion molecules and cytokines

T. Aune, M. Blue, Michael R Bombara, 1993, Journal of leukocyte biology.

Synthesis and pharmacological characterization of a potent, orally active p38 kinase inhibitor.

S. Wilhelm, W. Scott, J. Pirro, 2002, Bioorganic & medicinal chemistry letters.

Discovery of a new class of p38 kinase inhibitors.

J. S. Johnson, S. Wilhelm, W. Scott, 2000, Bioorganic & medicinal chemistry letters.

Chronic therapy with recombinant tumor necrosis factor-α in autoimmune NZB/NZW F1 mice

D. Wofsy, J. Greenspan, G. Ranges, 1989 .

Inheritance of Tolerance Susceptibility to Human γ-Globulin in Congenic Mice

G. Ranges, M. Azar, 1979, The Journal of Immunology.

Inheritance of tolerance susceptibility to human gamma-globulin in congenic mice.

G. Ranges, M. Azar, 1979, Journal of immunology.

Genetic control of tolerance induction to human gamma-globulin in mice.

E. Yunis, G. Ranges, M. Azar, 1978, Journal of immunology.

In vivo modulation of murine collagen induced arthritis.

S. Sriram, G. Ranges, S. Cooper, 1988, International reviews of immunology.

Abstract 2577: In vitro and in vivo efficacy of the anti-MN immunoconjugate BAY 79-4620, MN-IC, in MN (CAIX) expressing preclinical tumor models

K. Ziegelbauer, A. Voznesensky, G. Ranges, 2010 .

Immunotherapy of autoimmune disease with T cell subset specific antibodies.

S. Sriram, G. Ranges, 1987, Concepts in immunopathology.

In vivo immunomodulation by monoclonal anti-CD4 antibody. II. Effect on T cell response to myelin basic protein and experimental allergic encephalomyelitis.

S. Sriram, G. Ranges, S. Cooper, 1988, Journal of immunology.

Cell contact between T cells and synovial fibroblasts causes induction of adhesion molecules and cytokines

T. Aune, M. Blue, G. Ranges, 1993, Journal of leukocyte biology.

Inhibition of ceramide pathway does not affect ability of TNF-alpha to activate nuclear factor-kappa B.

G. Ranges, L. D. Johns, T. Sarr, 1994, Journal of immunology.